... a favorable environment for promising issuers in the dietary supplement market and attracts investors’ attention to the segment. The capital market in Russia has demonstrated record activity in 2024, with 19 IPOs completed, and the healthcare and pharmaceuticals sectors are among the leaders in the number of placements. In such conditions, investments in IPOs of food supplement companies are viewed as an interesting opportunity for portfolio diversification – provided that thorough fundamental ...

... for the week: Palantir will report amid hype around AI, BioNTech will present results following a vaccine boom, while Tyson and ON Semiconductor's data will showcase consumer demand trends for food and chips, respectively. After market close: Vertex Pharmaceuticals, Williams Companies, Axon Enterprise, Diamondback Energy. Investors will examine a wide range of results from biotechs (Vertex) and security technologies (Axon) to energy (Williams – gas transportation, Diamondback – oil extraction)....

... once again purchase popular models from brands such as Honda, Nissan, Mazda and Mitsubishi. This easing of sanctions supports the Russian car market and brings competition back to the automotive sector. Easing restrictions on the export of medical and pharmaceutical technologies: Some European Union countries have partially lifted restrictions on the export of certain medical and pharmaceutical technologies. This applies, for example, to equipment for the production of drugs, which will allow Russian ...

... in metrics compared to last year's record figures is anticipated; however, investors will concentrate on management comments and forecasts. Additionally, utility company Dominion Energy will report, illustrating trends in electricity and gas supply. Pharmaceuticals and Biotech: Biotechnology firm Moderna and pharmaceutical company Regeneron Pharmaceuticals will publish their reports. Moderna, experiencing a sharp decline in revenue following a boom in vaccine demand, is likely to report a loss for ...

... under control. A positive forecast from management for the second half of the year (for instance, regarding the continued trend of full demand recovery) will signal to investors about further attractiveness in the leisure and tourism sector. AbbVie (Pharmaceuticals): The pharmaceutical giant, one of the leaders in the S&P 500, will report quarterly results before trading begins. Analysts have moderately positive expectations: adjusted earnings of $2.90-2.95 per share (+~10% year-on-year) and revenues ...